Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $66.00 at Needham & Company LLC
Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its target price increased by Needham & Company LLC from $64.00 to $66 ...
Rhythm Pharmaceuticals Receives Orphan-Drug Designation in Japan for Obesity Treatment
Rhythm Pharmaceuticals received an orphan-drug designation from Japan's Ministry of Health, Labour and Welfare for its treatment for a certain type of obesity.
Charles Schwab Investment Management Inc. Acquires 6,384 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)
Charles Schwab Investment Management Inc. grew its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by ...
Rhythm Pharmaceuticals price target raised to $66 from $64 at Needham
Needham raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $66 from $64 and keeps a Buy rating on the shares. The firm sees ...
TipRanks on MSN18d
Rhythm Pharmaceuticals Faces Financial Risks Due to Convertible Preferred Stock Prioritization
Rhythm Pharmaceuticals (RYTM) has disclosed a new risk, in the Share Price & Shareholder Rights category. Rhythm Pharmaceuticals faces a business ...
Yahoo Finance2d
Rhythm Pharmaceuticals, Inc. (RYTM)
Over the last 7 days, the United States market has dropped 3.1%, yet it remains up by 13% over the past year with earnings anticipated to grow by 14% per annum in the coming years. In this dynamic ...
Nasdaq28d
7 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know
In the last three months, 7 analysts have published ratings on Rhythm Pharmaceuticals (NASDAQ:RYTM), offering a diverse range of perspectives from bullish to bearish. The following table ...
Hosted on MSN1mon
Earnings call transcript: Rhythm Pharmaceuticals Q3 2024 sees growth
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported its third-quarter 2024 earnings, highlighting a steady increase in revenue and strategic developments in product innovation and market expansion.
Seeking Alpha22d
Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven
Rhythm Pharmaceuticals' 01/2025 presentation and Q4 2024 preliminary results press release highlight growing financial performance and promising pipeline developments. Investment thesis focuses on ...
Nasdaq12d
Assessing Rhythm Pharmaceuticals: Insights From 10 Financial Analysts
10 analysts have shared their evaluations of Rhythm Pharmaceuticals (NASDAQ:RYTM) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a ...
Rhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare ...